Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats

Clin Sci (Lond). 2021 Oct 29;135(20):2409-2422. doi: 10.1042/CS20210405.

Abstract

Oxidative stress could be a possible mechanism and a therapeutic target of atrial fibrillation (AF). However, the effects of the xanthine oxidase (XO) inhibition for AF remain to be fully elucidated. We investigated the effects of a novel XO inhibitor febuxostat on AF compared with allopurinol in hypertension rat model. Five-week-old Dahl salt-sensitive rats were fed either low-salt (LS) (0.3% NaCl) or high-salt (HS) (8% NaCl) diet. After 4 weeks of diet, HS diet rats were divided into three groups: orally administered to vehicle (HS-C), febuxostat (5 mg/kg/day) (HS-F), or allopurinol (50 mg/kg/day) (HS-A). After 4 weeks of treatment, systolic blood pressure (SBP) was significantly higher in HS-C than LS, and it was slightly but significantly decreased by treatment with each XO inhibitor. AF duration was significantly prolonged in HS-C compared with LS, and significantly suppressed in both HS-F and HS-A (LS; 5.8 ± 3.5 s, HS-C; 33.9 ± 23.7 s, HS-F; 15.0 ± 14.1 s, HS-A; 20.1 ± 11.9 s: P<0.05). Ca2+ spark frequency was obviously increased in HS-C rats and reduced in the XO inhibitor-treated rats, especially in HS-F group. Western blotting revealed that the atrial expression levels of Met281/282-oxidized Ca2+/Calmodulin-dependent kinase II (CaMKII) and Ser2814-phosphorylated ryanodine receptor 2 were significantly increased in HS-C, and those were suppressed in HS-F and HS-A. Decreased expression of gap junction protein connexin 40 in HS-C was partially restored by treatment with each XO inhibitor. In conclusion, XO inhibitor febuxostat, as well as allopurinol, could reduce hypertension-related increase in AF perpetuation by restoring Ca2+ handling and gap junction.

Keywords: atrial fibrillation; calcium handling; gap junction; oxidative stress; xanthine oxidase inhibitor.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allopurinol / pharmacology
  • Animals
  • Atrial Fibrillation / enzymology
  • Atrial Fibrillation / genetics
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / prevention & control*
  • Calcium Signaling
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / genetics
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
  • Connexins / genetics
  • Connexins / metabolism
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology*
  • Febuxostat / pharmacology*
  • Fibrosis
  • Gap Junction alpha-5 Protein
  • Gap Junctions / drug effects
  • Gap Junctions / enzymology
  • Gap Junctions / pathology
  • Hypertension / drug therapy*
  • Hypertension / enzymology
  • Hypertension / genetics
  • Hypertension / physiopathology
  • Male
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / pathology
  • Oxidation-Reduction
  • Phosphorylation
  • Rats
  • Rats, Inbred Dahl
  • Ryanodine Receptor Calcium Release Channel / metabolism
  • Sodium Chloride, Dietary
  • Xanthine Oxidase / antagonists & inhibitors*
  • Xanthine Oxidase / metabolism

Substances

  • Connexins
  • Enzyme Inhibitors
  • RyR2 protein, rat
  • Ryanodine Receptor Calcium Release Channel
  • Sodium Chloride, Dietary
  • Febuxostat
  • Allopurinol
  • Xanthine Oxidase
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2